Table 1. Patient characteristics.
| Overall | Patients treated with Vemurafenib group A | Patients treated with TMZ/FM group B | |
| n. 39 | n. 19 | n. 20 | |
| Median age | 52 yrs (28–83) | 54 yrs (28–83) | 51 yrs (34–80) |
| Sex Male | 23 | 12 | 11 |
| Female | 16 | 7 | 9 |
| Stage IV | |||
| M1a | 7 | 4 | 3 |
| M1b | 9 | 4 | 5 |
| M1c | 23 | 11 | 12 |
| Metastatic sites | |||
| lung | 21 | 11 | 10 |
| liver | 7 | 4 | 3 |
| spleen | 3 | 0 | 3 |
| lymph nodes | 23 | 11 | 12 |
| soft tissue | 15 | 10 | 5 |
| bone | 9 | 6 | 3 |
| brain | 7 | 3 | 4 |
| other (gastric, adrenal gland) | 2 | 0 | 2 |
| BRAF gene | |||
| V600E/K | 22 | 19 | 3 |
| wt | 17 | 0 | 17 |
| DCR | 61% | 84% | 35% |
| Median PFS | 5 (2÷29+) | 5 (2÷26+) | 3 (2÷29+) |
| Median OS | 8 (2÷29+) | 8 (4÷26+) | 8 (2÷29+) |
All samples were tested only for genetic evaluation of BRAF status.